<DOC>
	<DOCNO>NCT02323022</DOCNO>
	<brief_summary>The purpose study compare clinical efficacy safety IAC regimen IA regimen induction chemotherapy initial diagnosed AML patient . 840 case suppose recruit 3 year .</brief_summary>
	<brief_title>Idarubicin Plus Cytarabine ( IA ) v IA Plus Cladribine ( IAC ) Induction Regimen Treat Initially Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cladribine</mesh_term>
	<criteria>Initially diagnose AML ( except APL ) Aged 18 60 year old Eastern Cooperative Oncology Group ( ECOG ) score 3 Informed consent file ( ICF ) sign AML secondary chronic leukemia myeloproliferative disease ( MPD ) APL With underlying malignancy except AML Uncontrolled severe infection Intolerant chemotherapy organically include : Heart failure : ejection fraction ( EF ) less 30 % , New York Heart Association ( NYHA ) grade high Grade II Liver kidney dysfunction : serum bilirubin≥2mg/dl , AST≥2.5*upper limit normal ( ULN ) , serum creatine≥2.5mg/dl Refuse participate trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AML</keyword>
	<keyword>cladribine</keyword>
	<keyword>induction therapy</keyword>
</DOC>